A novel therapeutic vaccine targeting the soluble TNFα receptor II to limit the progression of cardiovascular disease: AtheroVax™

The burden of atherosclerotic cardiovascular disease contributes to a large proportion morbidity and mortality, globally. Vaccination against atherosclerosis has been proposed for over 20 years targeting different mediators atherothrombosis; however, these have not adequately evaluated in human clinical trials assess safety efficacy. Inflammation is driver atherosclerosis, but inflammatory are essential components the immune response. Only pathogenic forms sTNFR2 acted upon while preserving membrane-bound (wild-type) TNFR2 contributions non-pathogenic We hypothesize that inhibition sTNRF2 will be more specific offer long-term treatment options. Here we describe pre-clinical findings an sTNFR2-targeting peptide vaccine (AtheroVax™) mouse model. multiple pathways synthesis soluble TNFRII receptor (sTNFRII) were identified as sTNFRII(PC), sTNFRII(Δ7), sTNFRII(Δ7,9). sTNFRII(Δ7) peptide, NH2-DFALPVEKPLCLQR-COOH based on mRNA splice-variant which exon 6 joined 8. role mediator prolonged TNFα activity by preventing degradation clearance was investigated. critical onset, progression expansion atherosclerosis. ligand represents inflammation mediated splice variant TNFR2, referred sTNFRII(Δ7). TNFRII, both membrane bound soluble, associated with distinctly phenotypes. sTNFRII(PC) equivalent etanercept because they lack mechanism. unique contains linear B-cell epitope amino acids from 8 supporting design. Animal studies evaluate ongoing, results forthcoming. limiting A therapeutic greatly contribute reduction mortality disease. It likely used combination current standards care lifestyle modifications.